Company Overview
Nihon Science Innovation and Solutions Inc. (NSiS) is a biotechnology company developing next-generation protein production technologies based on fully human cellular systems.
Our mission is to provide researchers and manufacturers with access to authentic human proteins that better reflect native human biology and accelerate advances in regenerative medicine, cell therapy, and biologics development.
| Headquarters | 7F, Yaesu Central Tower, Chuo-ku, Tokyo, Japan |
|---|---|
| Capital and Capital Surplus | JPY 50 million |
| Established | April 2025 |
Business Areas
- Human growth factors for regenerative medicine
- Monoclonal antibody library development using high-purity human antigens
- Next-generation biotechnology platforms powered by quantum biology
- Global manufacturing infrastructure for pandemic preparedness and response
Intellectual Property
- Japanese Patent No. 7645562, Method for Synthesizing Secreted Proteins (Granted)
- PCT International Patent Application, Method for Synthesizing Biomolecules (Filed in 2025)
- Ongoing expansion of our intellectual property portfolio through additional patent filings
Grants & Awards
- Tokyo Metropolitan Government Startup Grant Program (2025)
- Monozukuri Subsidy Program – International Expansion Program (2025)
Development Roadmap
From RUO today to GMP products by 2029
Contact Us
E-mail: info@nsis.co.jp